New Delhi, Jun 28 (PTI) Zydus Lifesciences Ltd on Wednesday said it has received tentative approval from the US health regulator for its generic Palbociclib tablets used to treat a certain type of breast cancer.

The tentative approval by the US Food and Drug Administration (USFDA) is for Palbociclib tablets of strengths 75 mg, 100 mg, and 125 mg, Zydus Lifesciences said in a regulatory filing.

Also Read | Car Insurance: Here Are Five Factors That Affect Car Insurance Premiums in India.

The drug is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

The product will be manufactured at the group's formulation manufacturing facility in SEZ, Ahmedabad, it added.

Also Read | PM Narendra Modi Likely To Visit Telangana on July 12 To Lay Foundation Stone for Railway Coach Periodic Overhauling Facility at Kazipet.

Palbociclib tablets, 75 mg, 100 mg, and 125 mg had annual sales of USD 3.3 billion in the US, the company said citing IQVIA MAT April 2023 data.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)